The affordability of antiretroviral therapy in developing countries: what policymakers need to know.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

The affordability of antiretroviral therapy in developing countries: what policymakers need to know.

AIDS. 1998;12 Suppl 2:S11-8. Unique Identifier : AIDSLINE MED/99006843
Forsythe SS; AIDSCAP/Family Health International.

Abstract: OBJECTIVE: The objective of this paper is to assist policymakers in developing countries and international donors by providing an outline of economic information needed to make a decision regarding the purchase of drugs to provide highly active antiretroviral therapy (HAART). DESIGN: The following paper: (i) reviews existing experiences of policymakers in developing countries regarding the purchase of drugs needed for HAART, (ii) identifies issues that would need to be addressed and data that would be required to make more informed decisions regarding this issue, (iii) develops a cost-benefit model that could be utilized in designing an economic research project evaluating the economic costs and benefits of HAART, and (iv) performs a preliminary test of this model with data from Costa Rica. RESULTS: A review of experiences with this issue reveals that there are growing political, legal and budgetary pressures for countries to make tenable decisions regarding the purchase of drugs for HAART. An economic model describing the costs and benefits of HAART is proposed, although much of the required data for using such a model is currently neither available or in the process of being collected. CONCLUSIONS: It is imperative that economic data be collected to better inform policymakers in developing countries about their decision regarding the purchase of these drugs. It is recommended that such economic data be collected as organizations such as the United Nations Joint Programme on HIV/ AIDS (UNAIDS) initiate their medical assessments of HAART in developing countries.

Keywords: JOURNAL ARTICLE Anti-HIV Agents/ADMINISTRATION & DOSAGE/*ECONOMICS/THERAPEUTIC USE Cost-Benefit Analysis Developing Countries Drug Costs Drug Therapy, Combination Human HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/ECONOMICS/ THERAPEUTIC USE Models, Economic Policy Making Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/ ECONOMICS/THERAPEUTIC USE Support, U.S. Gov't, Non-P.H.S.
990228
A9920944

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .